Usefulness of the Thyrotropin-Releasing Hormone Test in Pre-Clinical Acromegaly

Kageyama, Kazunori; Moriyama, Toshiyuki; Sakihara, Satoru; Takayasu, Shinobu; Nigawara, Takeshi; Suda, Toshio

doi:10.1620/tjem.206.291

Cited by 3 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding GH levels after OGTT and GH response to TRH test, nadir GH level above 1 μg/L and a two-fold increase of GH levels was used as an indication for GH excess, respectively. (Chin, et al 2013; Kageyama, et al 2005; Tzanela 2006)…”

Section: Methodsmentioning

confidence: 99%

Growth hormone and risk for cardiac tumors in Carney complex

Bandettini

Karageorgiadis

Sinaii

et al. 2016

Endocrine-Related Cancer

View full text Add to dashboard Cite

Carney Complex (CNC) is a multiple neoplasia syndrome that is caused mostly by PRKAR1A mutations. Cardiac myxomas are the leading cause of mortality in CNC patients who, in addition, often develop growth hormone (GH) excess. We studied patients with CNC who were observed for over a period of 20 years (1995–2015) for the development of both GH excess and cardiac myxomas. GH secretion was evaluated by standard testing; dedicated cardiovascular imaging was used to detect cardiac abnormalities. Four excised cardiac myxomas were tested for expression of insulin-like growth factor-1 (IGF-1). A total of 99 CNC patients (97 with a PRKAR1A mutation) were included in the study with a mean age of 25.8 ± 16.6 years at presentation. Over an observed follow-up mean of 25.8 years, 60% of patients with GH excess (n=46) developed a cardiac myxoma compared to only 36% of those without GH excess (n=54) (p=0.016). Patients with GH excess were also overall more likely to have a tumor versus those with normal GH secretion (OR=2.78, 95% CI: 1.23–6.29; p=0.014). IGF-1 mRNA and protein were higher in CNC myxomas than in normal heart tissue. We conclude that the development of cardiac myxomas in CNC may be associated with increased GH secretion, in a manner analogous to the association between fibrous dysplasia and GH excess in McCune Albright syndrome, a condition similar to CNC. We speculate that treatment of GH excess in patients with CNC may reduce the likelihood of cardiac myxoma formation and/or recurrence of this tumor.

show abstract

Section: Methodsmentioning

confidence: 99%

Growth hormone and risk for cardiac tumors in Carney complex

Bandettini

Karageorgiadis

Sinaii

et al. 2016

Endocrine-Related Cancer

View full text Add to dashboard Cite

show abstract

“…However, alternative tests have been proposed for the diagnosis of acromegaly such as the thyrotropin-releasing hormone (TRH) and Gonadotropin-releasing hormone (GnRH) stimulation tests, where a paradoxical GH increase is seen in acromegalic patients following their administration. Also, abnormal response of GH after L-Dopa administration has been seen in patients with acromegaly [9]. …”

Section: Introductionmentioning

confidence: 99%

The Coexistence of an Intrasellar Adenoma, Lymphocytic Hypophysitis, and Primary Pituitary Lymphoma in a Patient with Acromegaly

Martinez

Gorgola

et al. 2011

Case Reports in Endocrinology

View full text Add to dashboard Cite

The concomitant presence of three histopathologically different entities in the pituitary gland is a rare occurrence. Most publications identify at least two distinct pathologies, mainly, a pituitary adenoma coexisting with a second intrasellar lesion. We present a case of a 71-year-old female referred for evaluation and treatment of acromegaly. Questioning revealed she was experiencing facial palsy, visual disturbances, and syncopal spells for several weeks. When laboratory evaluation showed elevated somatomedin (IGF-I) levels and an oral glucose tolerance test failed to demonstrate any suppression of her growth hormone (GH) values, an MRI of the pituitary revealed a sellar mass. A presumptive diagnosis of pituitary adenoma was established. The patient underwent transsphenoidal resection of the sellar mass, which proved to be a large B-cell lymphoma (Stage I-E) associated with areas of adenoma and lymphocytic hypophysitis.

show abstract

The forgotten effects of thyrotropin-releasing hormone: Metabolic functions and medical applications

Frőhlich

Wahl

2019

Frontiers in Neuroendocrinology

View full text Add to dashboard Cite

Thyrotropin-releasing hormone (TRH) causes a variety of thyroidal and non-thyroidal effects, the best known being the feedback regulation of thyroid hormone levels. This was employed in the TRH stimulation test, which is currently little used. The role of TRH as a cancer biomarker is minor, but exaggerated responses to TSH and prolactin levels in breast cancer led to the hypothesis of a potential role for TRH in the pathogenesis of this disease. TRH is a rapidly degraded peptide with multiple targets, limiting its suitability as a biomarker and drug candidate. Although some studies reported efficacy in neural diseases (depression, spinal cord injury, amyotrophic lateral sclerosis, etc.), therapeutic use of TRH is presently restricted to spinocerebellar degenerative disease. Regulation of TRH production in the hypothalamus, patterns of expression of TRH and its receptor in the body, its role in energy metabolism and in prolactin secretion are addressed in this review.

show abstract

Usefulness of the Thyrotropin-Releasing Hormone Test in Pre-Clinical Acromegaly

Cited by 3 publications

References 18 publications

Growth hormone and risk for cardiac tumors in Carney complex

Growth hormone and risk for cardiac tumors in Carney complex

The Coexistence of an Intrasellar Adenoma, Lymphocytic Hypophysitis, and Primary Pituitary Lymphoma in a Patient with Acromegaly

The forgotten effects of thyrotropin-releasing hormone: Metabolic functions and medical applications

Contact Info

Product

Resources

About